| 张祥娥,陈愉生,李鸿茹.rs9904341多态性与肺癌易感性和铂类药物化疗敏感性的相关性[J].中国肿瘤,2012,21(7):533-538. |
| rs9904341多态性与肺癌易感性和铂类药物化疗敏感性的相关性 |
| The Relationship of rs9904341 Polymorphism with Lung Cancer Susceptibility and Sensitivity of Platinum-Based Chemotherapy in Patients with Lung Cancer |
| 投稿时间：2011-10-26 |
| DOI： |
|
 |
| 中文关键词: 肺癌 rs9904341 基因多态性 化疗 铂类药物 |
| 英文关键词:lung cancer rs9904341 gene polymorphism chemotherapy platinum drugs |
| 基金项目:福建省自然科学基金资助(2011J01130 )；福建省卫生厅青年科研基金资助（No.2010-2-7） |
|
| 摘要点击次数: 1509 |
| 全文下载次数: 1051 |
| 中文摘要: |
| 摘 要：［目的］ 探讨survivin基因启动子区rs9904341位点多态性与肺癌发生风险和晚期非小细胞肺癌(NSCLC)患者铂类药物化疗疗效的关系。［方法］ 通过聚合酶链反应—限制性酶切片断多态性方法（PCR-RFLP）检测289例健康对照组和289例肺癌患者的rs9904341多态性的基因型；其中130例晚期NSCLC仅接受铂类药物化疗，分析经2个周期化疗后的疗效及基因型与铂类药物化疗疗效和生存期的关系。［结果］ 基因型CC、CG、GG在肺癌组的分布频率分别为29.07%、47.05%、23.87%，在对照组的分布频率分别为20.42%、51.9%、27.68%，两组无显著性差异（P=0.053）。肺癌组中C等位基因和CC基因型的分布均显著高于对照组（P<0.05）。rs9904341多态性与晚期NSCLC患者铂类药物化疗有效率无显著相关性，但与临床受益率相关，GG基因型携带者的临床受益率是CC基因型者的2.06倍（95%CI：0.71~5.97，P=0.184）。对289例肺癌患者生存分析显示，CC基因型肺癌患者较CG+GG基因型预后差（95%CI:1.11~2.6，P=0.015）。［结论］ rs9904341多态性与肺癌的发病风险、预后及晚期NSCLC患者铂类药物化疗临床受益率相关。 |
| 英文摘要: |
| Abstract: ［Purpose］ To investigate the relationship of survivin gene promoter rs9904341 polymorphism with the risk of lung cancer and the effect of platinum-based chemotherapy on advanced NSCLC. ［Methods］ The genotypes of rs9904341 polymorphism in 289 lung cancer patients and 289 healthy person were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. In those lung cancer patients，130 cases with advanced NSCLC only received platinum-based chemotherapy，the clinical response was evaluated after 2 cycles，and the relationship of gene promoter polymorphism with susceptibility and survival of lung cancer was analyzed. ［Results］ The genotype frequencies for CC，CG，GG were 29.07%，47.05%，23.87% in lung cancer group，and 20.42%，51.9%，27.68% in control group respectively. No significant difference in the distribution of survivin genotype was found between the two groups(P=0.053). The frequencies of the C allele and CC genotype in lung cancer patients were significantly higher than those in healthy person (P<0.05). Analysis of 130 advanced NSCLC patients with platinum-based chemotherapy showed that no significant correlation of the rs9904341 polymorphism with response rate，but there is a relationship with the clinical benefit rate. The clinical benefit rate in GG genotype was 2.06 times of the CC genotype(95%CI:071～5.97，P=0.184) with survival analysis for the 289 cases with lung cancer，compared with CG+GG genotypes，the CC genotype was significantly associated with poor survival（95%CI:1.11～2.6，P=0.015）. ［Conclusion］ The rs9904341 polymorphism is closely associated with susceptibility and prognosis of lung cancer，and is significant association with clinical benefit response in advance NSCLC receiving platinum-based chemotherapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |